BI’s Article search uses Boolean search capabilities. If you are not familiar with these principles, here are some quick tips.
To search specifically for more than one word, put the search term in quotation marks. For example, “workers compensation”. This will limit your search to that combination of words.
To search for a combination of terms, use quotations and the & symbol. For example, “hurricane” & “loss”.
Reprints
Pharmacy benefit managers are significantly inflating drug costs for Americans, The New York Times reports. The three largest PBMs – Caremark (owned by CVS Health Corp.), Optum Rx (UnitedHealth Group Inc.), and Express Scripts (Cigna Group) – control 80% of U.S. prescriptions and often prioritize their financial interests over patients' needs, the report says. They push costlier drugs, impose high markups, and extract hidden fees, exacerbating health care expenses. Despite claims of cost-saving, PBM practices have led to higher out-of-pocket costs and limited access to affordable medications.
1. PBMs inflate drug costs, prioritize profits over patients: Report
2. Blue Shield of California fires executive for falsifying medical credentials
3. SCOTUS upholds $2.7 billion Blue Cross class action settlement
4. American Airlines faces trial over ESG options in its 401(k) plan
6. CBO: permanent ACA subsidies could add $335B to national deficit